Morgan Stanley
CARM

Morgan Stanley’s Carisma Therapeutics CARM Stock Holding History

Morgan Stanley’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,185
Closed -$873 – 8241
2025
Q3 		$873 Hold
3,185
– – ﹤0.01% 7403
2025
Q2 		$1.25K Sell
3,185
-2,500
-44% -$669 ﹤0.01% 7307
2025
Q1 		$1.76K Hold
5,685
– – ﹤0.01% 7198
2024
Q4 		$2.38K Hold
5,685
– – ﹤0.01% 7165
2024
Q3 		$5.58K Sell
5,685
-16,083
-74% -$17.4K ﹤0.01% 6886
2024
Q2 		$33.1K Sell
21,768
-19,508
-47% -$29.1K ﹤0.01% 6301
2024
Q1 		$93.7K Sell
41,276
-123,674
-75% -$297K ﹤0.01% 6015
2023
Q4 		$483K Buy
164,950
+138,021
+513% +$410K ﹤0.01% 5626
2023
Q3 		$114K Sell
26,929
-5,264
-16% -$33.3K ﹤0.01% 5826
2023
Q2 		$282K Buy
32,193
+25,447
+377% +$139K ﹤0.01% 5488
2023
Q1 		$20.9K Sell
6,746
-21,188
-76% -$202K ﹤0.01% 6613
2022
Q4 		$341K Sell
27,934
-7,970
-22% -$83.7K ﹤0.01% 5427
2022
Q3 		$305K Sell
35,904
-13,880
-28% -$189K ﹤0.01% 5516
2022
Q2 		$806K Buy
49,784
+37,229
+297% +$426K ﹤0.01% 5155
2022
Q1 		$152K Sell
12,555
-12,743
-50% -$178K ﹤0.01% 6066
2021
Q4 		$412K Sell
25,298
-7,374
-23% -$148K ﹤0.01% 5662
2021
Q3 		$518K Buy
32,672
+23,150
+243% +$1.11M ﹤0.01% 5472
2021
Q2 		$880K Buy
9,522
+9,253
+3,440% +$590K ﹤0.01% 5156
2021
Q1 		$14K Sell
269
-86,841
-100% -$4.1M ﹤0.01% 6837
2020
Q4 		$2.35M Buy
87,110
+21,922
+34% +$556K ﹤0.01% 4017
2020
Q3 		$1.83M Buy
65,188
+64,822
+17,711% +$1.3M ﹤0.01% 3735
2020
Q2 		$5K Buy
366
+123
+51% +$1.66K ﹤0.01% 6290
2020
Q1 		$2K Buy
243
+39
+19% +$639 ﹤0.01% 6371
2019
Q4 		$4K Buy
204
+85
+71% +$1.95K ﹤0.01% 6420
2019
Q3 		$3K Sell
119
-501
-81% -$11.7K ﹤0.01% 6427
2019
Q2 		$19K Buy
620
+526
+560% +$15.7K ﹤0.01% 5946
2019
Q1 		$2K Sell
94
-104
-53% -$1.8K ﹤0.01% 6443
2018
Q4 		$6K Buy
198
+4
+2% +$128 ﹤0.01% 6261
2018
Q3 		$8K Buy
194
+100
+106% +$3.9K ﹤0.01% 6349
2018
Q2 		$4K Sell
94
-266
-74% -$11.7K ﹤0.01% 6465
2018
Q1 		$7K Sell
360
-243
-40% -$4.67K ﹤0.01% 6334
2017
Q4 		$10K Buy
603
+253
+72% +$4.71K ﹤0.01% 6213
2017
Q3 		$11K Sell
350
-15
-4% -$419 ﹤0.01% 6150
2017
Q2 		$12K Buy
365
+3
+0.8% +$100 ﹤0.01% 6195
2017
Q1 		$16K Buy
362
+158
+77% +$6.58K ﹤0.01% 6134
2016
Q4 		$8K Sell
204
-19
-9% -$837 ﹤0.01% 6196
2016
Q3 		$13K Buy
223
+148
+197% +$11K ﹤0.01% 6043
2016
Q2 		$2K Buy
75
+65
+650% +$1.65K ﹤0.01% 6359
2016
Q1 		$0 Sell
10
-5
-33% -$69 ﹤0.01% 6576
2015
Q4 		$1K Sell
15
-75
-83% -$4.26K ﹤0.01% 6559
2015
Q3 		$4K Sell
90
-696
-89% -$42.9K ﹤0.01% 6410
2015
Q2 		$44K Buy
786
+613
+354% +$86.5K ﹤0.01% 5900
2015
Q1 		$31K Buy
173
+33
+24% +$7.21K ﹤0.01% 5944
2014
Q4 		$33K Sell
140
-14
-9% -$3.14K ﹤0.01% 5923
2014
Q3 		$34K Sell
154
-17
-10% -$4.04K ﹤0.01% 5843
2014
Q2 		$45K Buy
171
+55
+47% +$13.6K ﹤0.01% 5803
2014
Q1 		$37K Buy
+116
New +$34.7K ﹤0.01% 5811

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Morgan Stanley's CARM Position: Q4 2025 in Review

Morgan Stanley sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 3,185 shares — an estimated $873 sold.

Morgan Stanley first reported a position in CARM in Q1 2014 and held it in 47 quarters. The position peaked at $2.35M in Q4 2020. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Morgan Stanley reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 3,185 Carisma Therapeutics shares in Q4 2025, an estimated $873.
  • Morgan Stanley first reported a position in Carisma Therapeutics in Q1 2014 and held it in 47 quarters.
  • Morgan Stanley's Carisma Therapeutics position peaked at $2.35M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.